Company Analysis

Polyrizon Ltd. (PLRZ)

Nasdaq: PLRZ · Surgical & Medical Instruments & Apparatus · filing with the SEC since 2022
Grade6.3
◀ Past 7.2● Present 6.8▶ Future 4.7
7 est.
The companyfiscal 2025, as filed
Revenuen/a
Net income-$3.3M-115.9%
Earnings per share$4.90-99.4%
Operating cash flow-$4.5M-294.8%
Cash$1.3M-48.9%
Debtn/a
Shareholders’ equity$21.0M+297.2%
Shares, diluted680,380-65.9%
Return on equity-15.9%
The recordfrom its filings
Filings in 202664
Newest filingNov 9 · 8-A12B
Annual reportMar 25, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$100,000
Insider buys, 12 months$0.00
Patents granted1
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
22232425
As filed, in USD. Nothing here is a forecast.

News

Oct 1, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton PLRZ · research, not advice